Prognosis
Novo’s Wegovy Approved After Superior Weight-Loss Impact Shown
- Therapy showed average of 15% decline in body weight in trials
- Novo Nordisk aims to boost underused obesity medications
Wegovy injection pens
Source: Novo NordiskThis article is for subscribers only.
Novo Nordisk A/S gained U.S. approval for its therapy that helped patients lose about 15% of their body weight on average in trials, an alternative to an existing treatment from the Danish drugmaker as well as invasive, costly obesity surgery.
The drug, called Wegovy, will be available to obese adults and certain overweight people and should be used in conjunction with diet and exercise, Novo Nordisk said in a statement. About three-quarters of Americans are overweight or obese.